Market Overview

Eagle Pharmaceuticals Named to Fortune 100 List of Fastest-Growing Companies


--Achieves #1 ranking for both 3-year EPS and revenue growth--

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or "the Company")
today announced that the Company has been named to the Fortune 100 List
of Fastest-Growing Companies, ranking 16th overall, including
achieving the #1 positions for EPS 3-year growth of 392% and revenue
3-year growth of 109%.

"We are extremely proud of how our team has executed on our overall
growth strategy. We continue to see excellent opportunities ahead for
our business," stated Scott Tarriff, Chief Executive Officer of Eagle

Fortune's list ranks public companies, with market capitalization of
$250 million or more, based on revenue growth rate, EPS growth rate and
three-year annualized total return for the period ended June 30, 2018.

About Eagle Pharmaceuticals, Inc.

Eagle is a specialty pharmaceutical company focused on developing and
commercializing injectable products that address the shortcomings, as
identified by physicians, pharmacists and other stakeholders, of
existing commercially successful injectable products. Eagle's strategy
is to utilize the FDA's 505(b)(2) regulatory pathway. Additional
information is available on the company's website at

Forward-Looking Statements

This press release contains forward-looking information within the
meaning of the Private Securities Litigation Reform Act of 1995, as
amended and other securities laws. Forward-looking statements are
statements that are not historical facts. Words such as "will,"
"continue," "may," "believe," "intends," "anticipate(s)," "plan,"
"enables," "potentially," "entitles," and similar expressions are
intended to identify forward-looking statements. These statements
include statements regarding future events including, but not limited
to: Eagle's ability to defend against third party attempts to design
around or invalidate its patents; successful compliance with FDA and
other governmental regulations applicable to product approval,
manufacturing facilities, products and/or businesses; the FDA's ability
to approve any drug applications referencing BENDEKA prior to December
2022; the ability of generic TREANDA products to enter the market prior
to 2022; Eagle's market protection for BENDEKA; the commercial success
of Eagle's commercial portfolio, including BENDEKA; successful
compliance with FDA and other governmental regulations; the ability of
Eagle to deliver sustained shareholder value over time; and other
factors that are discussed in Eagle's Annual Report on Form 10-K for the
year ended December 31, 2017, and its other filings with the U.S.
Securities and Exchange Commission. All of such statements are subject
to certain risks and uncertainties, many of which are difficult to
predict and generally beyond Eagle's control, that could cause actual
results to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. Such risks
include, but are not limited to whether Eagle's management and/or board
of directors will be effective in managing Eagle's business and future
growth, as well as the other risks described in Eagle's filings with the
U.S. Securities and Exchange Commission. Readers are cautioned not to
place undue reliance on these forward-looking statements that speak only
as of the date hereof, and we do not undertake any obligation to revise
and disseminate forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of or
non-occurrence of any events.

View Comments and Join the Discussion!